| |
|
volgende >> |
|
aandeel @ 27-07-2010 17:24:53 (http://www.ErikErik.com / GTCB) |
|
bedankt plumo en knentjes |
|
knentjes @ 27-07-2010 15:56:32 (http://www.ErikErik.com / GTCB) |
|
bedoelde ik |
|
knentjes @ 27-07-2010 15:56:06 (http://www.ErikErik.com / GTCB) |
|
level2stockquotes.com (in usd) |
|
plumo @ 27-07-2010 15:56:01 (http://www.ErikErik.com / GTCB) |
http://www.otcmarkets.com/stock/gtcb/quote
hier heb je ook het orderboekje |
|
knentjes @ 27-07-2010 15:50:51 (http://www.ErikErik.com / GTCB) |
|
koers 0,34 rond |
|
aandeel @ 27-07-2010 15:46:26 (http://www.ErikErik.com / GTCB) |
|
is er nog een linkje zodat je de koers van gtcb kan volgen plumo? |
|
plumo @ 27-07-2010 15:21:21 (http://www.ErikErik.com / GTCB) |
|
mooie cijfers voor gtcb vandaag. |
|
plumo @ 16-07-2010 20:55:19 (http://www.ErikErik.com / GTCB) |
GTC Biotherapeutics Regains US Rights to ATryn® ; the First Recombinant Antithrombin Product Approved in the World
raar ???? |
|
jurpsy @ 16-06-2010 20:59:35 (http://www.ErikErik.com / GTCB) |
zij blijveu fan |
|
jurpsy @ 16-06-2010 20:59:02 (http://www.ErikErik.com / GTCB) |
|
+r |
|
jurpsy @ 16-06-2010 20:54:31 (http://www.ErikErik.com / GTCB) |
0.500 +0.080 (19.05%)
ut mot gezegd worden , de fansen blijven der in pompen... |
|
jurpsy @ 16-06-2010 14:24:27 (http://www.ErikErik.com / GTCB) |
GTC BIOTHERAPEUTICS ANNOUNCES NEW $7 MILLION FINANCING, COMPANY RESTRUCTURING AND MANAGEMENT CHANGES
Framingham, MA, June 16, 2010: GTC Biotherapeutics, Inc. (“GTC”, OTCBB: GTCB) announced the closing of a new $7 million secured convertible debt financing by its strategic partner, LFB Biotechnologies SAS (“LFB” Les Ulis, France), in connection with a restructuring of GTC’s operations which will result in a downsizing of approximately 30 full-time positions at its headquarters and an additional 20 positions at its farm facility. In addition, Geoffrey Cox and several other members of the current senior management team will be leaving GTC. Board member William Heiden has been named Chairman, CEO and President.
The convertible debt will mature on June 15, 2013 and will bear interest at an annual rate of 4%, with a single payment of principal and interest at maturity. LFB may convert the debt into GTC common stock at a conversion price of $ 0.42 per share at any time.
|
|
jurpsy @ 16-06-2010 14:23:51 (http://www.ErikErik.com / GTCB) |
Geoffrey Cox and several other members of the current senior management team will be leaving GTC. Board member William Heiden has been named Chairman, CEO and President.
de lul is er eindelijk uit!! |
|
ramonfey @ 12-05-2010 18:20:21 (http://www.ErikErik.com / GTCB) |
GTCB
/quotes/comstock/11k!gtcb
$0.50
Change
0.00 0.00%
Volume 14,120
May 12, 2010, 10:32 a.m.
/quotes/comstock/11k!gtcb
Previous close $0.50
$0.50
Change
0.00 0.00%
Day low
Day high
$0.48
$0.50
Open: 0.48 52 week low
52 week high
$0.45
$5.10
Market cap
$15.21M
Average volume
42,800
P/E ratio N/A
EPS N/A
Dividend
0.10
Div yield N/A
Ex dividend date
5/27/09
|
|
Soesje @ 12-05-2010 16:25:50 (http://www.ErikErik.com / GTCB) |
May 12, 2010 (Business Wire) -- GTC Biotherapeutics, Inc. ("GTC", OTCBB: GTCB) today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.
“GTC has continued to make good operational progress in its key programs during the first quarter,” stated Geoffrey Cox, Ph.D., Chairman, President and CEO of GTC Biotherapeutics. “Of particular importance are the preparations for the Phase I study for rhFVIIa which is on track for initiation in this second quarter.” |
|
jacky @ 15-04-2010 09:59:58 (http://www.ErikErik.com / GTCB) |
GTC Enters Into Atryn Registration License With Bio Sidus Argentina
GTC ENTERS INTO ATRYN® REGISTRATION LICENSE WITH BIO SIDUS ARGENTINA
FRAMINGHAM, MA – April 13, 2010 -- GTC Biotherapeutics, Inc. (“GTC”, OTCBB: GTCB) of Framingham, Massachusetts, and BIO SIDUS S.A. (“Bio Sidus”) of Buenos Aires, Argentina, announced that they have entered into a Registration License Agreement under which Bio Sidus will perform all necessary actions to obtain sales authorizations for GTC’s lead product, ATryn®, in Argentina, Uruguay and Paraguay. It is anticipated that the review process in Argentina will be completed within a fast-tracked period of no less than six (6) months from the filing of the dossier with the regulatory authorities. The dossier will be similar to that which was successfully submitted to the US Food and Drug Administration. All expenses incurred with respect to the filing, prosecution and obtaining of the sales authorizations will be borne by Bio Sidus.
A Product License agreement for the supply of material and marketing rights will be negotiated separately.
“This agreement demonstrates the continued worldwide interest in ATryn® as the only recombinant form of antithrombin. We are very excited to be working closely with Bio Sidus, a well-respected commercial biotechnology company, based in Latin America, with a strong international presence and an established interest in the production of therapeutic proteins using transgenic production technology” said Geoffrey Cox, Ph.D., Chairman, President & CEO of GTC Biotherapeutics.
“We are extremely pleased to enter into this landmark agreement with GTC which will lead to the satisfaction of unmet clinical demands in our region. The approval of ATryn® will also likely lead to acceptance by regulatory authorities, prescribers and the public of proteins derived from transgenic animals. We are confident that the transgenic production technology for targeted therapeutic proteins will be a key tool to obtain more affordable biomedicines. Biohormon®, Bio Sidus’ somatropin product obtained from the milk of transgenic cows, is also under review for marketing authorization in the near term, ” said Marcelo Argüelles, President of Bio Sidus S.A.
About GTC Biotherapeutics GTC Biotherapeutics develops supplies and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC’s recombinant human antithrombin, has been approved for use in the United States and Europe. ATryn® is the first and only therapeutic product produced in transgenic animals to be approved anywhere in the world. Building upon the 2009 FDA approval of ATryn®, GTC is collaborating with its US commercialization partner, Lundbeck Inc., to develop a protocol for a pivotal study of patients with acquired antithrombin deficiencies in cardiac surgery. GTC aims to initiate a clinical trial in this indication in the second half of 2010.
In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa and IX, which are being developed for the treatment of patients with hemophilia, and recombinant alpha-fetoprotein, which is being developed for the treatment of Myasthenia Gravis and Multiple Sclerosis. GTC plans to advance its human recombinant factor VIIa program into a Phase I clinical study in the first half of 2010 and its alpha-fetoprotein program into a Phase II study in Myasthenia Gravis in the second half of 2010 after securing a partner for that program.
GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enable cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
|
|
epper77 @ 13-04-2010 22:24:27 (http://www.ErikErik.com / GTCB) |
|
58 cent en amper volume, zo te zien is iedereen eruit |
|
botero @ 13-04-2010 17:48:17 (http://www.ErikErik.com / GTCB) |
)
Last Trade: 0.65
Trade Time: 11:24am ET
Change: 0.10 (18.18%
Vergeet niet op tijd ...................te stappen |
|
epper77 @ 30-03-2010 21:52:19 (http://www.ErikErik.com / GTCB) |
|
nhg was toen amper 2 ton ? nu 3 zoveel, zal jij wel boven zitten |
|
graaier @ 30-03-2010 21:51:17 (http://www.ErikErik.com / GTCB) |
ik heb nooit iets...  |
|
graaier @ 30-03-2010 21:51:03 (http://www.ErikErik.com / GTCB) |
was een  |
|
graaier @ 30-03-2010 21:50:30 (http://www.ErikErik.com / GTCB) |
|
ik niet... |
|
epper77 @ 30-03-2010 21:49:57 (http://www.ErikErik.com / GTCB) |
|
yep |
|
graaier @ 30-03-2010 21:49:37 (http://www.ErikErik.com / GTCB) |
|
hebbie NHG? |
|
epper77 @ 30-03-2010 21:47:37 (http://www.ErikErik.com / GTCB) |
|
en 5,1% bij 10 jaar is niet veel, maar ik zit nu op 3,4 voor 7 jaar en kan strax 4,3 bij 5 jaar worden of 4,8 bij 10 jaar ofzo. |
| |
